IP Library Granted Patent US 7,288,390
Granted Patent B2
US 7,288,390 · App. 09/920,267 · Granted Oct 30, 2007

Anti-dual integrin antibodies, compositions, methods and uses

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,288,390
App. No.
09/920,267
Granted
Oct 30, 2007
Kind
B2
Abstract

The present invention relates to at least one novel anti-dual integrin antibodies, including isolated nucleic acids that encode at least one anti-dual integrin antibody, dual integrin, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

Claims (14)

1. An isolated nucleic acid encoding an isolated mammalian anti-dual integrin antibody comprising (i) all of the heavy chain CDR amino acid sequences of SEQ ID NOS:1, 2, and 3; or (ii) all of the light chain CDR amino acids sequences of SEQ ID NOS:4, 5, and 6.

2. An isolated nucleic acid vector comprising an isolated nucleic acid according to claim 1 .

3. A prokaryotic or eukaryotic host cell comprising an isolated nucleic acid according to claim 2 .

4. A host cell according to claim 3 , wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, P3X63Ag8.653, SP2/0, HeLa, myeloma, or lymphoma cells.

5. A method for producing an anti-dual integrin antibody, comprising translating a nucleic acid vector according to claim 2 under conditions in vitro or in vivo, such that the dual integrin antibody is expressed in detectable or recoverable amounts.

6. An isolated nucleic acid encoding a human monoclonal antibody comprising human heavy chain and human light chain variable regions comprising the amino acid sequences shown in SEQ ID NO: 7 and SEQ ID NO: 8, respectively.

7. An isolated nucleic acid vector comprising an isolated nucleic acid according to claim 6 .

8. A prokaryotic or eukaryotic host cell comprising an isolated nucleic acid vector according to claim 7 .

9. A host cell according to claim 8 , wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, P3X63Ag8.653, SP2/0, 293, HeLa, myeloma, or lymphoma cells.

10. A method for producing an anti-dual integrin antibody, comprising translating a nucleic acid vector according to claim 7 under conditions in vitro or in vivo, such that the dual integrin antibody is expressed in detectable or recoverable amounts.

11. An isolated nucleic acid according to claim 6 wherein the antibody completely inhibits M21 cell adhesion to vitronectin.

12. An isolated nucleic acid according to claim 6 wherein the antibody comprises a human IgG heavy chain and a human kappa light chain.

13. An isolated nucleic acid according to claim 6 wherein the antibody comprises an IgG1 or IgG3 heavy chain.

14. An isolated nucleic acid according to claim 6 wherein the antibody is an IgG1kappa antibody.

Assignments (3)
MERGER Recorded Oct 7, 2013
From: CENTOCOR, INC.
To: CENTOCOR ORTHO BIOTECH INC.
Reel/Frame 031355/0001 →
CHANGE OF NAME Recorded Oct 7, 2013
From: CENTOCOR ORTHO BIOTECH INC.
To: JANSSEN BIOTECH, INC.
Reel/Frame 031377/0293 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2001
From: GILES-KOMAR, JILL; HEAVNER, GEORGE; SNYDER, LINDA; TRIKHA, MOHIT
To: CENTOCOR, INC.
Reel/Frame 012149/0235 →